Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33146976" target="_blank" >RIV/61989592:15110/14:33146976 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1016/S0140-6736(13)61719-5" target="_blank" >http://dx.doi.org/10.1016/S0140-6736(13)61719-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S0140-6736(13)61719-5" target="_blank" >10.1016/S0140-6736(13)61719-5</a>

Result language

angličtina

Original language name

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Original language description

Background Vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, prolonged survival in patients with advanced gastric cancer.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Lancet (Regional Edition)

ISSN

0140-6736

e-ISSN

—

Volume of the periodical

383

Issue of the periodical within the volume

9911

Country of publishing house

GB - UNITED KINGDOM

Number of pages

9

Pages from-to

31-39

UT code for WoS article

—

EID of the result in the Scopus database

—